Evelo Biosciences, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Evelo Biosciences, Inc. (EVLO) is a clinical-stage biotechnology company that discovers and develops oral medicines acting on immune cells in the small intestine to achieve systemic effects in treating inflammatory diseases and oncology indications; its core products include EDP1815, a whole-microbe candidate that completed Phase 2 trials in mild-to-moderate psoriasis and advanced into Phase 2 for atopic dermatitis, EDP2939, a next-generation extracellular vesicle product that initiated Phase 2 dosing in moderate psoriasis in 2023, EDP1867, a Veillonella parvula-based preparation in Phase 1b for inflammatory conditions, and EDP1908, an oncology-focused extracellular vesicle candidate progressing toward first-in-human studies. Founded in 2015 by Flagship Pioneering and headquartered in Cambridge, Massachusetts, the company operates primarily in the United States with a focus on the small intestinal axis (SINTAX) platform for modulating systemic immunity, inflammation, and metabolism without broad immunosuppression. Recent developments include a $25.5 million private placement in July 2023 led by Flagship Pioneering to fund the EDP2939 Phase 2a psoriasis trial readout and debt reduction, followed by a $79.2 million registered direct offering in late 2023 to advance EDP1815 registration trials in psoriasis and atopic dermatitis while progressing EDP2939; however, October 2023 top-line Phase 2 results for EDP2939 missed the primary endpoint, prompting cessation of its development, workforce reductions, and a strategic review for partnerships on EDP1815 and the SINTAX platform. As of late 2025, Evelo trades on OTC markets at minimal valuation amid ongoing pursuit of strategic alternatives.
Company News
Stock Traders Buy Large Volume of Evelo Biosciences Put Options (NASDAQ:EVLO)
Head to Head Review: Evelo Biosciences (NASDAQ:EVLO) vs. Silverback Therapeutics (NASDAQ:SBTX)
Evelo Biosciences Sees Unusually High Options Volume (NASDAQ:EVLO)
Stock Traders Buy High Volume of Evelo Biosciences Put Options (NASDAQ:EVLO)
Evelo Biosciences (NASDAQ:EVLO) vs. Vincerx Pharma (NASDAQ:VINC) Financial Analysis
Evelo Biosciences Sees Unusually High Options Volume (NASDAQ:EVLO)
Analyzing Evelo Biosciences (NASDAQ:EVLO) & Antibe Therapeutics (OTCMKTS:ATBPD)
EVLO to Provide Dominion Energy With Safety Enhanced Energy Storage Systems
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
Evelo Biosciences shares tank 46% after trial failure
Evelo Biosciences to review options after Phase 2 trial of psoriasis treatment fails to meet main goal
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
Evelo Biosciences: May Be Worth A Small, Highly Speculative Long Position Considering Upcoming Psoriasis Phase 2 Results
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
Evelo Biosciences Closes $25.5 Million Private Placement
Evelo Biosciences Announces $25.5 Million Private Placement
Why Is Evelo Biosciences (EVLO) Stock Up 51% Today?
What Makes Evelo Biosciences, Inc. (EVLO) a New Buy Stock
Discover the Top Penny Stock Technical Indicators By Effectiveness